Hemostemix Closes $480,000 Private Placement at $0.12 per Share

Core Viewpoint - Hemostemix Inc. has successfully closed a non-brokered private placement, raising CDN$480,000 through the issuance of 4,000,000 common shares at a price of $0.12 per share, aimed at advancing its autologous stem cell therapy initiatives [1][2]. Group 1: Financial Details - The private placement generated gross proceeds of CDN$480,000 [1]. - A total of 4,000,000 common shares were issued at a price of $0.12 per share [1]. Group 2: Use of Proceeds - The funds raised will be allocated for general working capital purposes, specifically to support regulatory, clinical, and commercialization efforts related to the ACP-01 (VesCell) therapy platform [2]. Group 3: Company Background - Hemostemix is an autologous stem cell therapy company founded in 2003, recognized as a World Economic Forum Technology Pioneer [4]. - The company has developed and patented VesCell™ (ACP-01), completing seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed publications [4]. - ACP-01 has shown significant clinical relevance and safety as a treatment for various ischemic conditions, including peripheral arterial disease and chronic limb threatening ischemia [4]. Group 4: Clinical Trial Results - Hemostemix completed a Phase II clinical trial for chronic limb threatening ischemia, reporting a 0% mortality rate and 83% wound healing in patients followed for up to 4.5 years, compared to a 50% mortality rate in the general patient population [4].